Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Total Consolidated Revenue by Quarter
Total Consolidated Revenue — Disaggregated by Payer & Product ($M) ($M)
Natera Total Consolidated Revenue: $753M in Q2 2026, up 37.7% from a year earlier. That is the highest of the 50 quarters on record here.
Latest, Q2 2026
753
Period ended Jun 30, 2026
Change on a year earlier
+37.7%
547 in Q2 2025
History
50 quarters
Since Q1 2014
Sources
40
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Reported in Form 10-K/10-Q Consolidated Statements of Operations & Revenue Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Consolidated Revenue — Disaggregated by Payer & Product ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 753 | +37.7% | Form 10-Q (2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 697 | +38.8% | Form 10-Q (2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 666 | +39.8% | Form 10-K (2026-02-27) ↗ |
| Q3 2025 | Sep 30, 2025 | 592 | +34.7% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 547 | +32.2% | Form 10-Q (2025-08-08) ↗ |
| Q1 2025 | Mar 31, 2025 | 502 | +36.5% | Form 10-Q (2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 476 | +53.0% | Form 10-K (2025-02-28) ↗ |
| Q3 2024 | Sep 30, 2024 | 440 | +63.9% | Form 10-Q (2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 413 | +58.1% | Form 10-Q (2024-08-09) ↗ |
| Q1 2024 | Mar 31, 2024 | 368 | +52.1% | Form 10-Q (2024-05-10) ↗ |
| Q4 2023 | Dec 31, 2023 | 311 | +43.2% | Form 10-K (2024-02-29) ↗ |
| Q3 2023 | Sep 30, 2023 | 268 | +27.4% | Form 10-Q (2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 261 | +31.9% | Form 10-Q (2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 242 | +24.6% | Form 10-Q (2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 217 | +25.6% | Form 10-K (2023-03-01) ↗ |
| Q3 2022 | Sep 30, 2022 | 211 | +33.2% | Form 10-Q (2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 198 | +39.6% | Form 10-Q (2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 194 | +27.4% | Form 10-Q (2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 173 | +53.9% | Form 10-K (2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 158 | +61.2% | Form 10-Q (2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 142 | +64.2% | Form 10-Q (2021-08-06) ↗ |
| Q1 2021 | Mar 31, 2021 | 152 | +62.0% | Form 10-Q (2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 112 | +35.1% | Form 10-K (2021-02-26) ↗ |
| Q3 2020 | Sep 30, 2020 | 98.1 | +25.9% | Form 10-Q (2020-11-06) ↗ |
| Q2 2020 | Jun 30, 2020 | 86.5 | +16.3% | Form 10-Q (2020-08-07) ↗ |
| Q1 2020 | Mar 31, 2020 | 94 | +40.7% | Form 10-Q (2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 83.2 | +24.2% | Form 10-K (2020-03-02) ↗ |
| Q3 2019 | Sep 30, 2019 | 77.9 | +19.3% | Form 10-Q (2019-11-08) ↗ |
| Q2 2019 | Jun 30, 2019 | 74.4 | +17.9% | Form 10-Q (2019-08-09) ↗ |
| Q1 2019 | Mar 31, 2019 | 66.8 | +7.2% | Form 10-Q (2019-05-10) ↗ |
| Q4 2018 | Dec 31, 2018 | 67 | +28.8% | Form 10-K (2019-03-15) ↗ |
| Q3 2018 | Sep 30, 2018 | 65.3 | +16.8% | Form 10-Q (2018-11-09) ↗ |
| Q2 2018 | Jun 30, 2018 | 63.1 | +20.7% | Form 10-Q (2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 62.3 | +26.1% | Form 10-K (2019-03-15) ↗ |
| Q4 2017 | Dec 31, 2017 | 52 | +5.5% | Form 10-K (2019-03-15) ↗ |
| Q3 2017 | Sep 30, 2017 | 55.9 | +3.7% | Form 10-Q (2018-11-09) ↗ |
| Q2 2017 | Jun 30, 2017 | 52.3 | +0.6% | Form 10-Q (2018-08-09) ↗ |
| Q1 2017 | Mar 31, 2017 | 49.4 | -20.2% | Form 10-K (2019-03-15) ↗ |
| Q4 2016 | Dec 31, 2016 | 49.3 | -6.8% | Form 10-K (2017-03-16) ↗ |
| Q3 2016 | Sep 30, 2016 | 53.9 | +20.0% | Form 10-Q (2016-11-14) ↗ |
| Q2 2016 | Jun 30, 2016 | 52 | +15.3% | Form 10-Q (2016-08-11) ↗ |
| Q1 2016 | Mar 31, 2016 | 61.9 | +30.6% | Form 10-Q (2016-05-13) ↗ |
| Q4 2015 | Dec 31, 2015 | 52.9 | +6.0% | Form 10-K (2016-03-24) ↗ |
| Q3 2015 | Sep 30, 2015 | 44.9 | -3.0% | Form 10-Q (2015-11-13) ↗ |
| Q2 2015 | Jun 30, 2015 | 45.1 | +26.0% | Form 10-Q (2015-08-13) ↗ |
| Q1 2015 | Mar 31, 2015 | 47.4 | +73.6% | Form 10-K (2016-03-24) ↗ |
| Q4 2014 | Dec 31, 2014 | 49.9 | – | Form 10-K (2016-03-24) ↗ |
| Q3 2014 | Sep 30, 2014 | 46.3 | – | Form 10-Q (2015-11-13) ↗ |
| Q2 2014 | Jun 30, 2014 | 35.8 | – | Form 10-Q (2015-08-13) ↗ |
| Q1 2014 | Mar 31, 2014 | 27.3 | – | Form 10-K (2016-03-24) ↗ |
Breakdown
What makes up total Consolidated Revenue
- Insurance Carriers Revenue — Third-Party Commercial & Government Payers ($M)705 · Q2 2026
- Laboratory Partners & Hospitals Revenue — Institutional Payers ($M)37.7 · Q2 2026
- Patients Revenue — Self-Pay & Out-of-Pocket Co-Pays ($M)9.92 · Q2 2026
- Panorama Non-Invasive Prenatal Test (NIPT) Revenue ($M) [legacy through Q3 2019]37.6 · Q3 2019
- Horizon Carrier Screening (HCS) Revenue ($M) [legacy through Q3 2019]26.2 · Q3 2019
- Other Genetic Tests Revenue ($M) [legacy through Q3 2019]3.23 · Q3 2019
- Constellation Cloud Software Platform Revenue ($M) [legacy through Q3 2019]1.25 · Q3 2019
- Other Licensing & Services Revenue ($M) [legacy through Q1 2020]0.80 · Q1 2020
Cite this data
StockData. (2026). Natera Total Consolidated Revenue ($M), quarterly Q1 2014–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rev-payer-disagg-parent
See every metric in the Natera KPI table. Data updated Nov 2, 2026.